Monday, January 14, 2008 8:40:30 AM
Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian CountriesLast update: 1/14/2008 8:30:00 AMDALLAS and NEW HAVEN, Conn., Jan 14, 2008 /PRNewswire-FirstCall via COMTEX/ -- Access Pharmaceuticals, Inc. (ACCP) and RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market, today announced the signing of a definitive licensing agreement under which RHEI, which has more than 110 national sales representatives penetrating large volume hospitals, will market Access's proprietary product MuGard(TM) in the Peoples Republic of China and certain other Southeast Asian countries. MuGard(TM) has received marketing allowance from the U.S. Food and Drug Administration for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Oral mucositis has become a significant unmet medical need as a result of improved medical care in China and the Southeast Asian region. RHEI will be responsible for marketing MuGard in the People's Republic of China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory. "We are pleased to have MuGard in our portfolio of products in China, building on our expertise in the area of oncology," said Dr. X. Sylvia He, Chief Executive Officer of RHEI. "Our mission is to bring innovative products to the Chinese market and MuGard fulfills a real medical need. With an increasing number of patients receiving radiation and chemotherapy in China, the prevalence of oral mucositis is growing. Our expert capabilities in sales and marketing, manufacturing and regulatory will help to maximize MuGard's potential in the marketplace." "RHEI is a great partner for us in China," added Jeffrey B. Davis, Chief Executive Officer of Access. "We are excited about the potential for MuGard in China and believe RHEI is uniquely positioned to commercialize MuGard in this region. We believe MuGard will fit very well with their existing portfolio of products and benefit from their aggressive marketing programs. We are also excited about the efficiency RHEI will obtain by manufacturing MuGard in their own GMP facility." About MuGard(TM):
http://custom.marketwatch.com/custom/tdameritrade-com/html-story.asp?guid={FC51DA6F-D0B1-4D75-9BA4-AFB9CE869139}
THE THRILL OF VICTORY ;-) & THE AGONY OF DEFEAT ;-(
Recent ABEO News
- Abeona Therapeutics Provides Regulatory Update on Pz-cel • GlobeNewswire Inc. • 04/22/2024 08:05:00 PM
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/01/2024 12:30:00 PM
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections • GlobeNewswire Inc. • 03/18/2024 11:30:00 AM
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/05/2024 12:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:20:25 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:15:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:38:19 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:30:11 PM
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/01/2024 09:05:00 PM
- Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA) • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 09:30:11 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:35:25 PM
- Abeona Therapeutics Announces $50 Million Credit Facility • GlobeNewswire Inc. • 01/08/2024 12:30:00 PM
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 12/15/2023 12:30:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/04/2023 09:09:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 12:30:12 PM
- Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA) • GlobeNewswire Inc. • 11/27/2023 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:01:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 12:35:13 PM
- Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments • GlobeNewswire Inc. • 11/13/2023 12:30:00 PM
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 11/01/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2023 11:30:22 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM